2nd Dec 2020 14:24
Surgical Innovations Group PLC - Leeds-based manufacturer of medical products for minimally invasive surgery - Says subsidiary Elemental Healthcare Ltd launches Cellis Breast, a new biological matrix range for breast reconstruction. Notes UK market for biological models for breast reconstruction is worth around GBP16 million and it therefore expects Cellis Breast to gain market share as reconstructive surgery resumes following deferrals due to Covid-19.
Current stock price: 1.48 pence
Year-to-date change: down 28%
By Ife Taiwo; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Surgical Innovations